Moderate beer consumption and the blood coagulation in patients with coronary artery disease

Journal of Internal Medicine

Volumn 241, Issue 1, 1997, Pages 47-51

  Gorinstein, S ^a   Zemser, M ^a   Lichman, I ^b   Berebi, A ^b   Kleipfish, A ^b   Libman, I ^b   Trakhtenberg, S ^b   Caspi, A ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b KAPLAN HOSPITAL   (Israel)

Author keywords

Alcohol consumption; Blood coagulation; Coronary artery disease; Factor VII; Fibrinogen; Plasminogen activator inhibitor; Prothrobmin time

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BEER; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL;

EID: 0031033426     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.77888000.x     Document Type: Article

References (36)

1. Renaud S, De Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-6.
2. Friedman LA, Kimball AW. Coronary heart disease and alcohol consumption in Framingham. Am J Epidemiol 1986; 124: 481-9.
3. Moor RD, Pearson TA. Moderate alcohol consumption coronary disease. Medicine 1986; 65: 246-67.
4. Marmor M, Brunner E. Alcohol and cardiovascular disease: the status of the U shape curve. Brit Med J 1991; 303: 565-8.
5. Klatsky AL, Armstrong MA, Friedman GD. Alcohol and mortality. Ann Intern Med 1992; 117: 646-54.
6. Jackson R, Scragg R, Beaglehole R. Alcohol consumption and risk of coronary artery disease. Brit Med J 1991; 303: 211-6.
7. Yano K, Rhoads GG, Kagan A. Coffee, alcohol and risk of coronary artery disease among Japanese men living in Hawaii. New Engl J Med 1977; 297: 405-9.
8. Langer RD, Criqui MH, Reed DM. Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary artery disease. Circulation 1992; 85: 910-5.
9. Suh I, Shaten BJ, Cutler JA, Kuller LH. Alcohol use and mortality from coronary artery disease: the role of high-density lipo-protein cholesterol. Ann Intern Med 1992; 116: 881-7.
10. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low density lipoprotein by phenolic substances in red wine. Lancet 1993; 341: 454-7.
11. Rankin SM, Whalley CV, Hoult JR, Jessup W, Wilkins GM, Collard J, et al. The modification of LDL by the flavonoids myricetin and gossypatin. Biochem Pharmacol 1993; 45: 67-75.
12. Buja LM, Willerson JT. The role of coronary artery lesions in ischemic heart disease. Hum Pathol 1987; 18: 451-61.
13. De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. New Engl J Med 1980; 303: 897-902.
14. Rapaport E. Thrombolitic agents in acute myocardial infarction. New Engl J Med 1989; 320: 861-4.
15. Brosins FC III, Roberts WS. Significance of coronary arterial thrombus in transmural acute myocardial infarction. A study of 54 necropsy patients. Circulation 1981; 63: 810-6.
16. GISSI. Effectiveness of intravenous thrombolytic treatment of acute myocardial infarction. Lancet 1986; i: 97-401.
17. GISSI. Long-term effects of intravenous thrombolysis in acute myocardial infarction. Lancet 1987; ii: 71-4.
18. ISIS-2. Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349-60.
19. Anglo-Scandinavian study of early thrombolysis (ASSET). Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; ii: 525-30.
20. GISSI-2. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
21. ISG. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-5.
22. ISIS-3. A randomized comparison of streptokinase versus tissue plasminogen activator versus antistreplase and of aspirin plus heparin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
23. Lee AJ, Lowe GDO, Woodward M. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history. The Scottish Heart Health Study. Br Heart J 1993; 69: 338-42.
24. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
25. Williams WG. Kinetics of plasma coagulation factors. In: MC Graw RP, Lerner M, eds. Hematology, 3rd edn. McGraw-Hill: 1983; 1222-65.
26. Ogston D, Bennett B. Blood coagulation mechanism. In: Poller J, ed. Blood Coagulation. Churchill Livingstone, New York: 1991: 1-15.
27. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2(4): 427-38.
28. Sharrett AR. The atherosclerosis risk in communities (ARIC) study. Introduction and objectives of the haemostasis components. Ann Epidemiol 1992; 2(4): 467-9.
29. Folsom AR, Conlan MG, Davis CE, Wu KK. Relation between haemostasis variables and cardiovascular risk factors in middle aged adults. Atherosclerosis risk in communities (ARIC) study investigations. Ann Epidemiol 1992; 2(4): 481-94.
30. Meade TW, North WR, Chakrabarti RR, Stirling Y, Haines AP, Thompson SG, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i: 1050-4.
31. Meade TW. Factor VII and ischemic heart disease: epidemiological evidence. Haemostasis 1983; 13: 178-85.
32. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
33. Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, et al. Association between dietary fat intake and plasma factor VII coagulant activity - a predictor of cardiovascular mortality. Atherosclerosis 1986; 60: 269-77.
34. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landon C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
35. Korninger C, Jager R, Huber K, Lechner K. Levels of plasminogen activator inhibitor in patients with angina pectoris. Klin Wochenschr 1988; 66(Suppl. XII): 59-61.
36. Olofsson BO, Dahlen G, Nilsson TK. Evidence of increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.